Evidence map›Paper›PMID 42420568›Full record

ArticleNature chemical biology2026

Tumor immune cell targeting chimeras reprogram tumor-associated macrophages.

Mariko Morimoto, David S Roberts, Ru M Wen, Ell Handy, Eric E Peterson, Grace M Stepek, Nicholas A Till, James D Brooks, Carolyn R Bertozzi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mariko Morimoto *Department of Chemistry, Stanford University, Stanford, CA, USA. mmorimot@nd.edu.ORCID http://orcid.org/0000-0001-8084-1042
David S Roberts *Department of Chemistry, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-0478-4987
Ru M WenDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Ell HandyDepartment of Chemistry, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0009-0004-7036-3429
Eric E PetersonDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5006-3865
Grace M StepekDepartment of Chemistry, University of Notre Dame, Notre Dame, IN, USA.
Nicholas A TillDepartment of Chemistry, Stanford University, Stanford, CA, USA.
James D BrooksDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-4521-7505
Carolyn R BertozziDepartment of Chemistry, Stanford University, Stanford, CA, USA. bertozzi@stanford.edu.ORCID http://orcid.org/0000-0003-4482-2754

Funding

METABOLIC OLIGOSACCHARIDE ENGINEERINGR01GM058867 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI Carolyn Bertozzi · 1999 to 2026
$5.6M
Metabolic Engineering with Bioorthogonal Chemical ReportersR37GM058867 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI BERTOZZI, CAROLYN · 2009 to 2018
$4.7M
500 MHz NMR Spectrometer System with High Sensitivity Cryoprobe and Automated Sample Changer for Biochemical ResearchS10OD028697 · OD · STANFORD UNIVERSITY · PI BURNS, NOAH ZACHARY · 2020 to 2020
$709k
A Metabolic Engineering Strategy to Map Sialyltransferase GlycositesF32GM143843 · NIGMS · STANFORD UNIVERSITY · PI TILL, NICHOLAS ALEXANDER · 2021 to 2023
$202k
Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation) DRG-2526-24NIGMS NIH HHS F32 GM143843NIGMS NIH HHS R01 GM058867NIGMS NIH HHS R37 GM058867NIH HHS S10 OD028697University of Notre Dame (University of Notre Dame du Lac) Startup grantU.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) F32GM143843U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) GM058867
6 · The paper itself

Abstract

Immune cells in the tumor microenvironment are not only powerful regulators of immunosuppression and tumorigenesis but also a dominant cell population, with tumor-associated macrophages (TAMs) comprising up to 50% solid tumor mass. Immunotherapies such as immune checkpoint inhibitors derive efficacy from this cancer-immune interface; however, immune-related adverse events from systemic blockade remain a major challenge. To address this need for potent, tumor-specific immunotherapies, we developed tumor immune cell targeting chimeras (TICTACs) that selectively deplete immune checkpoint receptors such as SIRPα from TAM surfaces. These chimeras consist of a synthetic ligand targeting CD206, a TAM marker, conjugated to a nonblocking antibody that binds to the checkpoint receptor without inhibiting it. By engaging CD206, which constitutively recycles between the plasma membrane and early endosomes, TICTACs drive robust checkpoint degradation in CD206

Identifiers

PMID42420568
PMCPMC13395576

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.